## **United Arab Emirates**



## **Tuberculosis**

Population 2010 (m	nillions)
--------------------	-----------


Estimates of burden * 2010	Number (thousands)	Rate (per 100 000 pop)
Mortality (excluding HIV)	0.023 (0.016-0.031)	0.3 (0.21–0.42)
Prevalence (incl HIV)	0.47 (0.2-0.84)	6.2 (2.7–11)
Incidence (incl HIV)	0.23 (0.16-0.31)	3.1 (2.1-4.2)
Incidence (HIV-positive)	<0.01 (<0.01-0.013)	0.05 (0-0.17)
Case detection, all forms (%)	57 (42-82)	

Case notifications 2010				
New cases		(%) Retreatment cases		(%)
Smear-positive	56	(43) Relapse	0	(0)
Smear-negative	28	(21) Treatment after failure	0	(0)
Smear unknown	0	(0) Treatment after default	1	(100)
Extrapulmonary	47	(36) Other	0	(0)
Other	0	(0)		
Total new	131	Total retreatment	1	
Total < 15 years	18			

Total new and relapse	131	(99% of total)
Total cases notified	132	

Drug regimens	
Rifampicin used throughout treatment	Yes
% of patients treated with fixed-dose combinations (FDCs)	0
Paediatric formulations procured	No


Treatment success rate 2009 (%)	
New smear-positive	73
New smear-negative/extrapulmonary	63
Retreatment	





MDR-TB, Estimates among notified cases *	
% of new TB cases with MDR-TB	1.2 (0.70-1.6)
% of retreatment TB cases with MDR-TB	9.0 (5.6–12)
Estimated MDR-TB cases among new pulmonary TB cases notified in 2010	1 (0.59–1.3)
Estimated MDR-TB cases among retreated pulmonary TB cases notified in 2010	0.09 (0.056–0.12)

MDR-TB reported cases 2010	New	Retreat- ment	Total
Cases tested for MDR-TB			
% of notified tested for MDR-TB			
Confirmed cases of MDR-TB			0
MDR-TB patients started treatment			0
Laboratories	2009	2010	2011
Smear (per 100 000 population)	0.3		
Culture (per 5 million population)	2.2		
DST (per 5 million population)	0		


Incidence (HIV+TB in orange), notifications (black) (rates per 100 000 population)








TB/HIV 2010
TB patients with known HIV status
% of TB patients with known HIV status
TB patients that are HIV-positive
% of tested TB patients that are HIV-positive
% HIV-positive TB patients started on CPT
% HIV-positive TB patients started on ART
HIV-positive people screened for TB
HIV-positive people provided with IPT
CPT (orange) and ART (green) for HIV-positive TB patients (



Financing	2011
Total budget (US\$ millions)	
Available funding (US\$ millions)	0
% of budget funded	
% available funding from domestic sources	
% available funding from Global Fund	
NTP Budget (blue) and available funding (green)	(US\$ million

Second-line DST available	No
National Reference Laboratory	No



Generated: August 28, 2011

<sup>\*</sup> Ranges represent uncertainty intervals